michigan semaglutide nausea law firm The Food and Drug Administration has approved a higher-dose version of the weight-loss drug Wegovy through a pilot program designed to accelerate drug approvals. The agency said Thursday that 7.2-milligram injectable doses A South African court has

But over and over, we talk to women who dont know four basic vital facts about this class of drugs

One workout won't give you six-pack abs, but showing up every day for three months will certainly change your life

When your hunger is under control, youre less likely to consume excess calories, which often leads to fat accumulation around your abdomen

Helps the body utilize stored fat as an energy source, supporting healthy fat-burning and weight-management goals

Triple Agonists (GLP-1/GIP/Glucagon) Class Overview Monograph At a glance Prototype agent / retatrutide (LY3437943), Eli Lilly Mechanism / simultaneous GLP-1R, GIPR, and glucagon receptor co-agonism Phase 2 peak weight loss / up to 24.2% body weight at 48 weeks (retatrutide 12 mg) Primary indications in development / obesity, type 2 diabetes, MASLD/MASH, dyslipidemia Route and frequency / once-weekly subcutaneous injection Key differentiator from dual agonists / added glucagon receptor activity drives hepatic fat mobilization and energy expenditure Most common adverse effects / nausea, vomiting, diarrhea, constipation (dose-dependent) Regulatory status (as of mid-2025) / phase 3 trials ongoing

Injection appointments are covered under naturopathic benefits and can be direct billed.